Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | ASAH2 | Q9NR71 | 2/20 | 0.71 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.70 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133213 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL13863420 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22973496 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL5527047 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22911186 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22973426 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL24032894 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22973497 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22910831 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22910800 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116568319-A | Method for reversing hepatic steatosis | 布莱特西德公司 | 2023-08-08 | — | — | CN | claimed |
| US-20120029331-A1 | IDENTIFICATION, DIAGNOSIS, AND TREATMENT OF NEUROPATHOLOGIES, NEUROTOXICITIES, TUMORS, AND BRAIN AND SPINAL CORD INJURIES USING ELECTRODES WITH MICROVOLTAMMETRY | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (US) | 2012-02-02 | — | — | US | claimed |
| EP-2137204-A1 | USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES | Amicus Therapeutics, Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| WO-2008128089-A1 | USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES | AMICUS THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| US-20070026440-A1 | Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using electrodes with microvoltammetry | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | 2007-02-01 | — | — | US | claimed |
| US-6830919-B1 | For ceramide metabolism/formation of fatty acid and sphingoid; genetic engineering; for treatment of metabolic disorders | TAKARA BIO INC. (JP) | 2004-12-14 | — | — | US | claimed |
| EP-0869185-B9 | Production of optically active sphingoid compound | SUMITOMO CHEMICAL CO (JP) | 2004-08-11 | — | — | EP | claimed |
| EP-0869185-B1 | Production of optically active sphingoid compound | SUMITOMO CHEMICAL CO (JP) | 2003-09-17 | — | — | EP | claimed |
| EP-4743440-A1 | IONIZABLE LIPIDS | eTheRNA immunotherapies NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4739663-A1 | IONIZABLE LIPIDS | eTheRNA immunotherapies NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12611419-B2 | Liposomal composition for use in a method of treating Parkinson's disease | INNOMEDICA HOLDING AG (CH) | 2026-04-28 | — | — | US | disclosed |
| WO-2026047192-A1 | IONIZABLE LIPIDS | ETHERNA IMMUNOTHERAPIES NV (BE) | 2026-03-05 | — | — | WO | disclosed |
| EP-4680721-A1 | BIOPRODUCTION OF GANGLIOSIDES IN RECOMBINANT HOST CELLS | Recombia Biosciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025217552-A1 | 2-(TERT-BUTYL)-4-METHYLPHENYL APPENDED 1,4-DIAZEPANE BASED NOVEL TFEB ACTIVATING COMPOUNDS AS AUTOPHAGY MODULATORS FOR NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S DISEASE (AD) | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2000037046-A1 | THERAPEUTIC DELIVERY USING COMPOUNDS SELF-ASSEMBLED INTO HIGH AXIAL RATIO MICROSTRUCTURES | UNIVERSITY OF WASHINGTON (US) | 2000-06-29 | — | — | WO | disclosed |
| US-6046040-A | Method for producing glycoconjugates | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2000-04-04 | — | — | US | disclosed |
| EP-0940409-A1 | PROCESS FOR THE PREPARATION OF SPHINGOLIPIDS AND SPHINGOLIPID DERIVATIVES | TAKARA SHUZO CO. LTD. (JP) | 1999-09-08 | — | — | EP | disclosed |
| EP-0897014-A2 | Method for producing glycoconjugates | Toyo Boseki Kabushiki Kaisha (JP) | 1999-02-17 | — | — | EP | disclosed |
| US-5851536-A | Therapeutic delivery using compounds self-assembled into high axial ratio microstructures | UNIVERSITY OF WASHINGTON (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0869185-A2 | Production of optically active sphingoid compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611419-B2 | Liposomal composition for use in a method of treating Parkinson's disease | SMPD2, SMPD1, SGMS2 | CETP 194/4885THRB 1059/4885MEN1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.